Malignant neoplasm of lung
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Using an RNase protection assay we have analyzed the expression of MRP in non-Pgp MDR sublines of the human lung cancer cell lines SW-1573 (non-small cell lung cancer) and GLC4 (small cell lung cancer).
|
8467491 |
1993 |
Non-Small Cell Lung Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Using an RNase protection assay we have analyzed the expression of MRP in non-Pgp MDR sublines of the human lung cancer cell lines SW-1573 (non-small cell lung cancer) and GLC4 (small cell lung cancer).
|
8467491 |
1993 |
Carcinoma of lung
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Using an RNase protection assay we have analyzed the expression of MRP in non-Pgp MDR sublines of the human lung cancer cell lines SW-1573 (non-small cell lung cancer) and GLC4 (small cell lung cancer).
|
8467491 |
1993 |
Primary malignant neoplasm of lung
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Using an RNase protection assay we have analyzed the expression of MRP in non-Pgp MDR sublines of the human lung cancer cell lines SW-1573 (non-small cell lung cancer) and GLC4 (small cell lung cancer).
|
8467491 |
1993 |
Small cell carcinoma of lung
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Using an RNase protection assay we have analyzed the expression of MRP in non-Pgp MDR sublines of the human lung cancer cell lines SW-1573 (non-small cell lung cancer) and GLC4 (small cell lung cancer).
|
8467491 |
1993 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of the multidrug resistance-associated protein (MRP), a new glycoprotein involved in drug resistance, was investigated in tumour samples from 80 patients with chronic B-cell malignancies by a quantitative RNase protection assay.
|
7803281 |
1994 |
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcriptase-polymerase chain reaction was used to measure MRP mRNA in normal hematopoietic cells from bone marrow and peripheral blood as well as patients with high risk acute myelocytic leukemia and multiple myeloma.
|
8062263 |
1994 |
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that MRP expression may be of prognostic importance in AML but the significance of the increased levels we have detected remain unclear.
|
7808005 |
1994 |
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that relatively high expression of MRP is occasionally observed in AML and at high frequency in CLL, irrespective of treatment, probably due to transcriptional activation and/or increased mRNA stability.
|
7911548 |
1994 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of the MRP gene is thus common in both primary neuroblastoma tumors and cultured cell lines, and correlates with amplification and overexpression of the N-myc oncogene, which is central to the malignant phenotype of this disease.
|
7923112 |
1994 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of the multidrug resistance-associated protein (MRP), a new glycoprotein involved in drug resistance, was investigated in tumour samples from 80 patients with chronic B-cell malignancies by a quantitative RNase protection assay.
|
7803281 |
1994 |
leukemia
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
These findings provide important insight into the biology of inversion 16 leukaemia and suggest that MRP deletion, as detected by molecular analysis, may have a key role in determining outcome in patients with inversion 16 AML.
|
7911871 |
1994 |
leukemia
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Southern blot analysis did not reveal amplification of the MRP gene in the leukaemia samples with elevated MRP mRNA levels.
|
7803281 |
1994 |
leukemia
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
DNA analysis by Southern blotting did not reveal amplification of the MRP gene in the leukemia samples, including those with elevated MRP mRNA levels.
|
7911548 |
1994 |
Neuroblastoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Expression of the MRP gene is thus common in both primary neuroblastoma tumors and cultured cell lines, and correlates with amplification and overexpression of the N-myc oncogene, which is central to the malignant phenotype of this disease.
|
7923112 |
1994 |
Acute lymphocytic leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We found a concomitant increase in mdr1 and mrp gene expression combined with a decreased expression of topoisomerase II alpha in the course of the second relapse of an acute lymphoblastic leukemia (ALL).
|
7914748 |
1994 |
Acute lymphocytic leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In contrast, low MRP expression levels were detected in acute lymphocytic leukemia (n = 14), and in chronic myelocytic leukemia (n = 9).
|
7911548 |
1994 |
Acute lymphocytic leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
MRP gene expression was found to be higher in patients with relapsed de novo AML compared to those at presentation but prior therapy did not affect MRP gene expression in ALL.
|
7808005 |
1994 |
Central neuroblastoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Expression of the MRP gene is thus common in both primary neuroblastoma tumors and cultured cell lines, and correlates with amplification and overexpression of the N-myc oncogene, which is central to the malignant phenotype of this disease.
|
7923112 |
1994 |
Childhood Neuroblastoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Expression of the MRP gene is thus common in both primary neuroblastoma tumors and cultured cell lines, and correlates with amplification and overexpression of the N-myc oncogene, which is central to the malignant phenotype of this disease.
|
7923112 |
1994 |
Chronic Lymphocytic Leukemia
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We conclude that relatively high expression of MRP is occasionally observed in AML and at high frequency in CLL, irrespective of treatment, probably due to transcriptional activation and/or increased mRNA stability.
|
7911548 |
1994 |
Chronic Lymphocytic Leukemia
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We conclude that B-PLL and B-CLL frequently display high MRP expression and that this hyperexpression is probably due to transcriptional activation and/or increased mRNA stability.
|
7803281 |
1994 |
Multiple Myeloma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
All myeloma patients (12 of 12) had detectable MRP mRNA expression at levels comparable to normal peripheral blood and bone marrow cells.
|
8062263 |
1994 |
Multiple Myeloma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In contrast, low MRP mRNA expression levels were detected in hairy cell leukaemia (n = 7), non-Hodgkin's lymphoma (n = 13) and multiple myeloma (n = 18).
|
7803281 |
1994 |
Childhood Leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
DNA analysis by Southern blotting did not reveal amplification of the MRP gene in the leukemia samples, including those with elevated MRP mRNA levels.
|
7911548 |
1994 |